This study is testing two medicines, remibrutinib and teriflunomide, to see which works better and is safer for people with relapsing multiple sclerosis (RMS). RMS is a condition where the immune system mistakenly attacks the brain and spinal cord, leading to various symptoms. The study lasts up to 30 months, with a possibility to continue for another 5 years if eligible. The first part is "double-blind", meaning neither the participants nor the researchers know who gets which medicine. After this, eligible participants may continue with remibrutinib openly for 5 more years.
- Duration: Up to 30 months initially, with a 5-year extension.
- Eligibility: Ages 18-55 with RMS; must meet certain health criteria.
- Risks: Potential side effects and health risks must be considered.
Participants must be between 18 to 55 years old and meet specific health criteria. They should not have certain other health issues like primary progressive multiple sclerosis or significant diseases. Before joining, discuss any personal health concerns with your doctor.